Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.64 USD | -0.13% | +1.33% | -46.21% |
Apr. 02 | QuidelOrtho Shares Fall on Decision to Withdraw FDA 510(k) Submission for Savanna RVP4+ Assay | MT |
Apr. 02 | QuidelOrtho Gets US FDA Clearance For QuickVue COVID-19 Test | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-46.21% | 2.65B | C+ | ||
-12.91% | 18.55B | A | ||
+18.15% | 1.81B | - | - | |
-3.12% | 1.61B | - | ||
+23.78% | 1.21B | B+ | ||
-10.69% | 1.03B | - | ||
-20.89% | 896M | - | C- | |
-18.10% | 686M | B+ | ||
-7.14% | 680M | - | ||
-.--% | 302M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- QDEL Stock
- Ratings QuidelOrtho Corporation